Transport layer protocol designed originally as part of the Plan 9 from Bell Labs operating system and used to carry 9P. In computing and telecommunications, the transport layer is level four of the seven level OSI model. ... This page is about the operating system; for the science fiction film, see Plan 9 from Outer Space. ... 9P, or the Plan 9 Filesystem Protocol, is a network protocol developed for the Plan 9 distributed operating system as the means of connecting the components of a Plan 9 system (site). ...
Its main features are:
Reliable datagram service
In-sequence delivery
Internetworking using IP
Low complexity, high performance
Adaptive timeouts
The original paper describing IL: [1] (http://plan9.bell-labs.com/sys/doc/il/il.pdf)
Protocol 1997-064 excludes patients with a history of corticosteroid use in the four weeks preceding entry into the study and states “patients who require corticosteroids are not eligible for this study.” Subject [redacted] was receiving corticosteroids due to seizures caused by brain metastases.
Protocol 1995-243 section 5.0 requires that several tests be performed and the results evaluated to determine that potential subjects would meet the protocol inclusion criteria, and did not have medical or other conditions that exclude them from the study.
Protocol section 8.1 and Appendix 1 require you to measure vital signs “prior to injection and once during the hour for two hours after injection, or more frequently as needed.” This was an important measurement to monitor the safety of the subject, especially for the first injection of the investigational product.
Protocol 1990-489 section 5.0 requires several tests to determine whether potential subjects met the protocol inclusion criteria and did not have conditions that excluded them from the study.
Protocol 1990-489 section 9.1 lists several procedures that must be performed as part of the pretreatment evaluation of subjects before administration of the activated cells and interfeukin-2 (IL-2).
Protocol section 8.4 states "the dose of IL-2 being administered is 360,000 IU/kg...." Table 1 defined the circumstances in which the dose of IL-2 could be modified and identifies only-two options: keeping the same dose (designated by "-"), or skipping a dose (designated by "Hold").
Feeds |
Contact